Corporate Information   

VIVUS, Inc. is a drug-development company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity, diabetes, sleep apnea and sexual health.

Analysts speculate that the potential market for obesity ranges from $5 billion to $10 billion annually, the potential market for an effective diabetes therapy that causes weight loss is in excess of $2 billion, sales of devices and related supplies to treat sleep apnea exceed $2 billion annually and the indications targeted by VIVUS' sexual health products each represent a projected market greater than $1 billion annually.

VIVUS' investigational pipeline includes:

• Qnexa® for obesity, which recently completed phase 3 development, with NDA filing in December 2009, and a PDUFA date of October 28, 2010.
• Qnexa for diabetes currently in phase 2. Data from the phase 2 diabetes study was initially announced in December 2008.
• Qnexa for obstructive sleep apnea currently in phase 2. Data from the phase 2 efficacy and safety study was announced in January 2010.
• Avanafil which is currently in phase 3 development for the treatment of erectile dysfunction (ED).
• Luramist^™, for which a phase 2 study has been completed for the treatment of hypoactive sexual desire disorder (HSDD).